Skin Cancer
KEYNOTE-716 trial - Pembrolizumab outcome
-TN23-Skin.png)
In the phase III #KEYNOTE-716 trial published in the Lancet, Adjuvant #pembrolizumab improved the clinical outcomes compared to placebo in...
SWOG S1801 trial
In SWOG S1801 study presented by Dr. Sapna Patel, #neoadjuvant treatment (NAT) with #pembrolizumab showed a significant EFS benefit compared...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)